Pfizer may face lawsuits regarding improper marketing of Neurontin after a Boston court reinstated lawsuits that had been denied class-action status by lower courts. The court also upheld a $142.1 million award against Pfizer for damages related to the marketing of Neurontin.
Article →
Of further interest:Court upholds $142 mln verdict against Pfizer over Neurontin (Reuters)Pfizer fails to block $142M Neurontin award, faces 2 more suits (Fierce Pharma)
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at
[email protected] .
